MannKind rises as FDA updates label for inhaled insulin Afrezza

MannKind

26/01/2026 11:51

** Shares of drugmaker MannKind MNKD.O rise 8% to $5.89 premarket

** Co says U.S. FDA approved a new label for its inhaled insulin product, Afrezza, used at mealtime to control blood sugar in adults with diabetes

** Co says update gives doctors clearer steps on how to switch patients from injected insulin to the inhaled version

** MNKD's Afrezza is taken through a small inhaler at the start of meals, per co

** Studies cited by co show improved control of after‑meal blood sugar spikes - MNKD

** Co says Afrezza should not be used by people with asthma, COPD or smokers due to breathing-related risks

** Most common side effects include low blood sugar, cough and throat irritation, co says

** Shares down ~12% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))